View full meeting coverage »

Eyetube Meeting Coverage:

OIS RETINA 2018

You are watching a 25-second preview
Log in to keep watching

You are watching a 25-second preview Log in to keep watching

You are watching a 25-second preview
Log in to keep watching

Replay

Cancel

Your 25-second video preview has ended.

to continue watching, please Log In or Register:

Log in / Register

Spark Therapeutics

Paulo Falabella, MD, PhD

Channels: Retina | Posted 7/23/2018

Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.

Luxturna (Spark Therapeutics)

9 / 11 Series: OIS RETINA 2018

Paulo Falabella, MD, PhD Channels: Retina | Posted 7/23/2018

Paulo Falabella, MD, PhD, Medical Director, Ophthalmology, Spark Therapeutics, talks about the significance of the approval of Luxturna (voretigene neparvovec-rzyl), which was the first gene therapy for an inherited disease approved in the United States.

Keywords

Luxturna (Spark Therapeutics)

Comments view all

. United States - today

Post Comment
post as anonymous

More Videos in this Series

1

GenSight Biologics

Barrett Katz, MD

RFE Pharma

Alan Franklin, MD, PhD

EyePoint Pharmaceuticals

Tom Hadley

Zeiss

ZeaVision Holdings

Pinakin Davey, OD, PhD

iRenix

Stephen Smith, MD

Clearside Biomedical

Brion Raymond

Aerie Pharmaceuticals

Vince Anido Jr, PhD

Spark Therapeutics

Paulo Falabella, MD, PhD

Allegro

Vicken Karageozian, MD

Eyedaptic

Jay Cormier

View full meeting coverage (11 videos)

1

Allegro

Vicken Karageozian, MD

Eyedaptic

Jay Cormier